Stocktoria
Aclaris Therapeutics, Inc. ACRS
Aclaris Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M | $6.5M | $4.2M | $6.2M | $1.7M | — |
| Gross profit | — | — | — | — | — | — | — | $3.2M | $476,000 | — |
| R&D expense | $52.6M | $33.6M | $98.4M | $77.8M | $43.8M | $29.3M | $64.2M | $60.8M | $35.8M | $33.5M |
| Operating income | -$76.4M | -$141.9M | -$97.4M | -$89.9M | -$89.7M | -$50.9M | -$111.1M | -$84.8M | -$54.4M | -$48.6M |
| Income tax | — | — | -$367,000 | — | — | -$182,000 | — | — | -$1.8M | — |
| Net income | -$64.9M | -$132.1M | -$88.5M | -$86.9M | -$90.9M | -$51.0M | -$161.4M | -$132.7M | -$68.5M | -$48.1M |
| EPS (diluted) | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 | $-1.20 | $-3.90 | — | — | — |
| Operating cash flow | -$47.1M | -$20.1M | -$78.3M | -$67.6M | -$52.1M | -$38.6M | -$96.4M | -$100.8M | -$54.7M | -$34.6M |
| Free cash flow | -$47.2M | -$20.2M | -$79.6M | -$68.2M | -$52.4M | -$39.1M | -$98.1M | -$102.2M | -$55.9M | -$34.8M |
| Cash & equivalents | $20.0M | $24.6M | $39.9M | $45.3M | $27.3M | $22.1M | $34.2M | — | $20.2M | $30.2M |
| Inventory | — | — | — | — | — | — | $0 | $791,000 | — | — |
| Total assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M | $70.8M | $98.3M | $275.6M | $243.5M | $176.1M |
| Total liabilities | $57.4M | $64.8M | $40.2M | $57.0M | $53.9M | $33.1M | $28.4M | $60.4M | $18.2M | $6.6M |
| Shareholders' equity | $103.1M | $155.6M | $157.2M | $197.6M | $197.3M | $37.6M | $69.9M | $215.1M | $225.3M | $169.5M |
Growth · year-over-year · Revenue CAGR 21.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -58.2% | -40.1% | +5.0% | +340.1% | +4.3% | +53.3% | -31.3% | +265.5% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.